MAPT and Alzheimer disease: Raja et al. [12] demonstrated that familial AD patient-derived organoids exhibited AD-like pathophysiological features in a culture system, and treatment of the organoids with γ-secretase inhibitor compound E or a β-secretase inhibitor partially reversed amyloid and tau pathology [12].